These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12132015)

  • 1. A new TB drug by 2010--or sooner?
    Crabb C
    Bull World Health Organ; 2002; 80(6):518-9. PubMed ID: 12132015
    [No Abstract]   [Full Text] [Related]  

  • 2. [Maxaquin in the combined treatment of tuberculosis].
    Sokolova GB; Mozhokina GN; Kunichan AD; Elistratova NA; Perel'man MI
    Probl Tuberk; 2000; (5):35-9. PubMed ID: 11077850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.
    Showalter HD; Denny WA
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S3-17. PubMed ID: 18762151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New antibacterial agents].
    Vaara M; Saxén H
    Duodecim; 1999; 115(20):2259-64. PubMed ID: 11973930
    [No Abstract]   [Full Text] [Related]  

  • 5. New tuberculosis therapeutics: a growing pipeline.
    Spigelman MK
    J Infect Dis; 2007 Aug; 196 Suppl 1():S28-34. PubMed ID: 17624823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy.
    Kalita A; Verma I; Khuller GK
    J Infect Dis; 2004 Oct; 190(8):1476-80. PubMed ID: 15378441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES; Mallampalli A
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trench warfare in a battle with TB.
    Marshall E
    Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790
    [No Abstract]   [Full Text] [Related]  

  • 9. Tuberculosis drug development: progress, challenges, and the road ahead.
    Ginsberg AM
    Tuberculosis (Edinb); 2010 May; 90(3):162-7. PubMed ID: 20382086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.
    Wallis RS; Jakubiec WM; Kumar V; Silvia AM; Paige D; Dimitrova D; Li X; Ladutko L; Campbell S; Friedland G; Mitton-Fry M; Miller PF
    J Infect Dis; 2010 Sep; 202(5):745-51. PubMed ID: 20629533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination.
    Koenig R
    Science; 2008 Feb; 319(5865):894-7. PubMed ID: 18276863
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
    Cox HS; Niemann S; Ismailov G; Doshetov D; Orozco JD; Blok L; Rüsch-Gerdes S; Kebede Y
    Clin Infect Dis; 2007 Jun; 44(11):1421-7. PubMed ID: 17479936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
    Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
    J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
    Nam HS; Koh WJ; Kwon OJ; Cho SN; Shim TS
    Int J Antimicrob Agents; 2009 Jan; 33(1):92-3. PubMed ID: 18789655
    [No Abstract]   [Full Text] [Related]  

  • 16. Post-antibiotic effects of linezolid and other agents against Mycobacterium tuberculosis.
    Hui M; Au-Yeang C; Wong KT; Chan CY; Yew WW; Leung CC
    Int J Antimicrob Agents; 2008 Apr; 31(4):395-6. PubMed ID: 18272351
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():762-7. PubMed ID: 12722313
    [No Abstract]   [Full Text] [Related]  

  • 18. [Linezolid, an agent from a new class of antibiotics].
    Slebos DJ; Van Altena R
    Ned Tijdschr Geneeskd; 2004 Dec; 148(49):2462; author reply 2462-3. PubMed ID: 15626313
    [No Abstract]   [Full Text] [Related]  

  • 19. Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome.
    Rusen ID; Aït-Khaled N; Alarcón E; Billo N; Bissell K; Boillot F; Caminero J; Chiang CY; Clevenbergh P; Dhliwayo P; Dlodlo R; Enarson DA; Ferroussier O; Fujiwara PI; Heldal E; Hinderaker SG; Kim SJ; Lienhardt C; Rieder HL; Trébucq A; Van Deun A; Wilson N
    Int J Tuberc Lung Dis; 2007 Feb; 11(2):120-1. PubMed ID: 17263279
    [No Abstract]   [Full Text] [Related]  

  • 20. [Surveillance of resistance of Mycobacterium tuberculosis to anti-TB drugs in Cuba, 1995-1998].
    Montoro E; Echemendía M; Lemus D; Marrero A; Llanes MJ; Valdivia JA
    Biomedica; 2004 Jun; 24 Supp 1():80-4. PubMed ID: 15495575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.